logo-loader
viewPolarean Imaging PLC

Polarean installs second Xenon Polariser at SickKids hospital in Toronto

The new unit will expand the research at the hospital and bring Polarean’s total number of the installed and on-order polarisers to 24

Polarean Imaging PLC installs second unit at SickKids hospital in Toronto

Polarean Imaging PLC (LON:POLX) has delivered and installed its latest 9820 Xenon Polariser system at the Hospital for Sick Children in Toronto.

The Xenon Polariser is a drug-device system that uses hyperpolarised 129-Xenon gas to make magnetic resonance imaging (MRI) more effective in assessing lung function.

‘SickKids’, a major paediatric research and teaching hospital, had been part of an ongoing research programme using an earlier model polariser that has been upgraded.

The second unit, which was enabled by a grant from the Canada Foundation for Innovation, will expand this research and bring Polarean’s total number of the installed and on-order polarisers to 24.

“The purchase of this second polariser will significantly improve our capabilities to image children faster and with higher image quality, enabling several new paediatric lung MRI projects,” said SickKids senior scientist Giles Santyr.

Quick facts: Polarean Imaging PLC

Price: 20 GBX

AIM:POLX
Market: AIM
Market Cap: £22.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Polarean Imaging eagerly awaiting readouts from its key phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen speaks to Proactive London's Andrew Scott following the news they've now completed patient enrolment for the phase III clinical trials of its MRI lung scan technology. He says the trials are now in the image and statistical analysis stage, a...

1 month ago

2 min read